{
  "source": "PA-Notification-Orkambi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1160-13\nProgram Prior Authorization/Notification\nMedication Orkambi® (lumacaftor/ivacaftor)\nP&T Approval Date 5/2015, 7/2016, 11/2016, 11/2017, 9/2018, 9/2019, 9/2020, 9/2021,\n9/2022, 10/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nOrkambi is a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane\nconductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in\npatients aged 1 years and older who are homozygous for the F508del mutation in the CFTR\ngene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to\ndetect the presence of the F508del mutation on both alleles of the CFTR gene.1\nLimitations of Use:\nThe efficacy and safety of Orkambi have not been established in patients with CF other than\nthose homozygous for the F508del mutation.1\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Orkambi will be approved based upon all of the following criteria:\na. Diagnosis of cystic fibrosis (CF)\n-AND-\nb. Documentation confirming the patient is homozygous for the F508del mutation in the\nCFTR gene.\n-AND-\nc. The patient is ≥ 1 years of age\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Orkambi will be approved based on the following criterion:\na. Documentation of positive clinical response to Orkambi therapy (e.g., improved lung\nfunction, stable lung function)\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication histo",
    "gement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits, Medical Necessity may be in place.\n4. References:\n1. Orkambi [Package Insert]. Cambridge, MA: Vertex Pharmaceuticals, Inc.; December 2024.\nProgram Prior Authorization/Notification - Orkambi®(lumacaftor/ivacaftor)\nChange Control\n5/2015 New Program\n7/2016 Annual Review. Updated reference.\n11/2016 Program updated modifying age restriction as label updated for\npediatric use in patients age 6 and older. Updated reference.\n11/2017 Annual Review. No changes.\n9/2018 Program updated modifying age restriction as label updated for\npediatric use in patients age 2 and older.\n9/2019 Annual review with no changes to clinical coverage criteria.\n9/2020 Annual review with no changes to clinical coverage criteria.\n9/2021 Annual review. Reauthorization updated from 24 months to 12 months.\n9/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote.\n10/2022 Updated background and criteria with expanded indication in patients\naged 1 to 2 years. Updated reference.\n6/2023 Simplified reauthorization criteria. Updated reference.\n6/2024 Annual review. Increased initial authorization approval duration to 12\nmonths. Updated reference.\n6/2025 Annual review. No changes to coverage criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}